The August 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Carnival, Ciena, MercadoLibre, Spark Therapeutics, Smith & Wesson, Teva Pharmaceutical and Verifone.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include DDR, HP, L-3 Communications, Salesforce.com, Teva Pharmaceutical and Twilio.
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was lower.
Allergan reported mixed second-quarter 2016 results and announced share buybacks before markets opened Monday morning.
The top analyst upgrades, downgrades and initiations seen on Friday morning include FireEye, Occidental Petroleum, SeaWorld, Teva Pharmaceutical, Windstream and Zynga.
Teva Pharmaceutical Industries is scheduled to release its second-quarter financial results before the markets open on Thursday.
24/7 Wall St. has put together a preview of Pfizer, Chesapeake Energy and other major companies reporting their quarterly results this week.
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
Lucky for Teva Pharmaceuticals, interest rates on all kinds of debt have never been lower in recorded human history, and they keep getting lower even beyond basic logic.
Even though the trend toward generic drugs is only likely to grow, the drug price pressures hanging over the sector also hurt most generic drug makers.
The June 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest decreased.
Viagra, the wildly successful erectile dysfunction pill, faces challenges from a generic version that will launch next year.
The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity…
